For your appropriate hypertensive patients turn to TEKTURNA HCT—proven BP reductions in mild-to-moderate hypertension1,2
The primary endpoint was change in msDBP from baseline to week 8.
Change from baseline in msSBP (mm Hg)
-
Tekturna HCT
150/12.5 mg-18
-
Tekturna HCT
150/25 mg-20
-
Tekturna HCT
300/12.5 mg-20
-
Tekturna HCT
300/25 mg-21
Mean baseline SBP 153-155 mm Hg (TEKTURNA HCT)
Least square means (LSM) change from baseline in msSBP (mm Hg)
Mean non-placebo–subtracted DBP in study (mm Hg).
Change from baseline in msDBP (mm Hg)
-
Tekturna HCT
150/12.5 mg-12
-
Tekturna HCT
150/25 mg-13
-
Tekturna HCT
300/12.5 mg-14
-
Tekturna HCT
300/25 mg-14
Mean baseline DBP 153-155 mm Hg (TEKTURNA HCT)
Least square means (LSM) change from baseline in msDBP (mm Hg)
Mean non-placebo–subtracted DBP in study (mm Hg).
Study design
TEKTURNA HCT was studied in an 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, multifactorial study in patients with mild-to-moderate hypertension (msDBP 95-109 mm Hg). The mean baseline SBP/DBP range was 153-155/99-100 mm Hg. The primary endpoint in this trial was change in msDBP from baseline to week 8.
Turn to TEKTURNA HCT
- As initial therapy in patients likely to need multiple drugs to achieve BP goals2
- For patients whose BP is not adequately controlled with aliskiren or hydrochlorothiazide (HCTZ) monotherapy2
Patients with BP ≥160/100 (formerly stage 2 hypertension)
For your appropriate hypertensive patients turn to TEKTURNA for BP ≥160/100 (formerly stage 2 hypertension)3
TEKTURNA HCT: proven BP reductions in patients with BP ≥160/100 (formerly stage 2 hypertension)3
-
TEKTURNA HCT (N=346)
300/25 mg-30
Baseline msSBP 167 mm Hg*
Least square means (LSM) change from baseline in msSBP (mm Hg) at primary endpoint
Efficacy was compared with aliskiren 300 mg (n=335), which achieved msSBP reductions of -20 mm Hg at week 12.
*Patients with stage 2 hypertension.
Study design
A 12-week, double-blind, randomized, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared with aliskiren 300 mg in patients with BP ≥160/100 (formerly stage 2 hypertension). The primary efficacy variable was the change from baseline (visit 2/day 1) in msSBP at endpoint. For each patient, the last postbaseline measurement during the double-blind period was carried forward to week 12 as the endpoint measurement.3
At week 12, change from baseline in msDBP was -8 mm Hg for aliskiren 300 mg and -13 mm Hg for aliskiren 300 mg and hydrochlorothiazide 25 mg.3
TEKTURNA HCT safety profile: extensively studied in more than 2700 patients2
Common adverse events (AEs) with TEKTURNA HCT vs placebo2
AE | TEKTURNA HCT | Placebo |
---|---|---|
Dizziness | 2.3% | 1.0% |
Influenza | 2.3% | 1.6% |
Diarrhea | 1.6% | 0.5% |
Cough | 1.3% | 0.5% |
Vertigo | 1.2% | 0.5% |
Asthenia | 1.2% | 0% |
Arthralgia | 1.0% | 0.5% |
*At 300 mg.
†Does not include AEs from the ALTITUDE study.
TEKTURNA HCT discontinuation rates due to AEs less than placebo
- 2.7% of study population for TEKTURNA HCT vs 3.6% on placebo
TEKTURNA HCT is available in 4 dosage strengths
TEKTURNA HCT dosing considerations
-
TEKTURNA HCT is dosed once daily2
- The usual recommended starting dose is 150/12.5 mg once daily as needed to control BP
- The dose may be titrated up to a maximum dose of 300/25 mg
-
Patients should take TEKTURNA HCT at the same time every day2
- TEKTURNA HCT can be taken with or without food
- Patients should establish a routine for taking TEKTURNA HCT with meals
Antihypertensive effect largely manifested within 1 week. Maximal effects generally seen at ≈4 weeks.2
References: 1. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25(1):217-226. 2. Tekturna HCT [prescribing information]. Boston, MA: Noden Pharma USA Inc; 2016. 3. Data on file. Clinical study report 2353. Novartis Pharmaceuticals Corp.